NEOPHARM's CINTREDEKIN BESUDOTOX Highlighted in Presentations at the Congress of Neurological Surgeons (CNS) Annual Meeting

NEOPHARM, Inc. (NASDAQ/NM: NEOL): WHO/WHAT: NEOPHARM, Inc. (NASDAQ/NM: NEOL) clinical data presentations on CINTREDEKIN BESUDOTOX ("IL13-PE38QQR")   WHERE: Congress of Neurological Surgeons (CNS) 2006 Annual Meeting October 7-12, 2006 McCormick Place Convention Center Chicago, Ill.   WHEN: Monday, October 9, 2006 Oral Poster Session: Section on Tumors I Select Abstract Session Time: 3:30 - 4:15 p.m. Abstract: #130 Title: Intraparenchymal Convection-Enhanced Delivery of CINTREDEKIN BESUDOTOX: Results of Multicenter Phase I Studies in Recurrent Malignant Glioma Authors: Sandeep Kunwar, MD; Zvi Ram, MD; John H. Sampson, MD, PhD; Michael Prados, MD; Susan Chang, MD; Frederick F. Lang, MD; Joseph M. Piepmeier, MD; Philip H. Gutin, MD; David J. Croteau, MD; Raj K. Puri, MD, PhD   Wednesday, October 11, 2006 Symposium: Section on Tumors II Special Symposium: Convection Enhanced Delivery (CED) Time: 4:00 - 5:30 p.m. Moderators: Sandeep Kunwar, MD; Michael Vogelbaum, MD, PhD Following Dr. Kunwar’s October 9th presentation, and Dr. Kunwar’s and Dr. Vogelbaum’s October 11th special symposium, copies of the poster and symposium presentation on the summary of clinical trials using CED can be found at www.neopharm.com/index.php?section=24. NEOPHARM’s Commitment to Oncology NEOPHARM employees share a common goal: bringing hope to cancer patients and their families through the research and development of new cancer drugs and therapies. The Company's oncology portfolio is built on two novel, proprietary platforms: a tumor-targeting platform, and the NeoLipid® Liposomal Drug Delivery platform. Through its research and clinical studies, as well as its work with physicians, scientists, and advocacy groups, NEOPHARM is helping to enhance the lives of cancer patients. About NEOPHARM, Inc. NEOPHARM, Inc., based in Waukegan, Illinois, is a publicly traded biopharmaceutical company dedicated to the research, development and commercialization of new and innovative cancer drugs for therapeutic applications. Additional information, including ongoing clinical trials, can be obtained by visiting NEOPHARM's Web site at www.neopharm.com. Forward Looking Statements - This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. The Company has tried to identify such forward-looking statements by use of such words as "expects," "intends," "hopes," "anticipates," "believes," "could," "may," "evidences" and "estimates," and other similar expressions, but these words are not the exclusive means of identifying such statements. Such statements include, but are not limited to, any statements relating to the Company’s drug development program, including, but not limited to, clinical trials involving CINTREDEKIN BESUDOTOX, future patient survival in the Company’s ongoing Phase I/II studies for CINTREDEKIN BESUDOTOX, the use of the CED procedure and any other statements that are not historical facts. Such statements involve risks and uncertainties, including, but not limited to, those risks and uncertainties relating to difficulties or delays in financing, development, testing, obtaining regulatory approval, production and marketing of CINTREDEKIN BESUDOTOX, unexpected side effects or inadequate therapeutic efficacy of CINTREDEKIN BESUDOTOX that could slow or prevent CINTREDEKIN BESUDOTOX from coming to market, uncertainty regarding the Company's ability to market its drug and non-drug products including, but not limited to, CINTREDEKIN BESUDOTOX, and other risks detailed from time to time in filings the Company makes with the Securities and Exchange Commission including its annual reports on Form 10-K and quarterly reports on Forms 10-Q. Such statements are based on management's current expectations, but actual results may differ materially due to various factors, including those risks and uncertainties mentioned or referred to in this press release. Accordingly, you should not rely on these forward-looking statements as a prediction of actual future results.